Literature DB >> 11535535

P-selectin mediates the adhesion of sickle erythrocytes to the endothelium.

N M Matsui1, L Borsig, S D Rosen, M Yaghmai, A Varki, S H Embury.   

Abstract

The adherence of sickle red blood cells (RBCs) to the vascular endothelium may contribute to painful vaso-occlusion in sickle cell disease. Sickle cell adherence involves several receptor-mediated processes and may be potentiated by the up-regulated expression of adhesion molecules on activated endothelial cells. Recent results showed that thrombin rapidly increases the adhesivity of endothelial cells for sickle erythrocytes. The current report presents the first evidence for the novel adhesion of normal and, to a greater extent, sickle RBCs to endothelial P-selectin. Studies of the possible interaction of erythrocytes with P-selectin revealed that either P-selectin blocking monoclonal antibodies or sialyl Lewis tetrasaccharide inhibits the enhanced adherence of normal and sickle cells to thrombin-treated endothelial cells. Both RBC types also adhere to immobilized recombinant P-selectin. Pretreating erythrocytes with sialidase reduces their adherence to activated endothelial cells and to immobilized recombinant P-selectin. Herein the first evidence is presented for the binding of normal or sickle erythrocytes to P-selectin. This novel finding suggests that P-selectin inhibition be considered as a potential approach to therapy for the treatment of painful vaso-occlusion in sickle cell disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11535535     DOI: 10.1182/blood.v98.6.1955

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  70 in total

1.  Inhibition of cell adhesion by anti-P-selectin aptamer: a new potential therapeutic agent for sickle cell disease.

Authors:  Diana R Gutsaeva; James B Parkerson; Shobha D Yerigenahally; Jeffrey C Kurz; Robert G Schaub; Tohru Ikuta; C Alvin Head
Journal:  Blood       Date:  2010-10-06       Impact factor: 22.113

Review 2.  The paradox of the neutrophil's role in tissue injury.

Authors:  George B Segel; Marc W Halterman; Marshall A Lichtman
Journal:  J Leukoc Biol       Date:  2010-11-19       Impact factor: 4.962

Review 3.  Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease.

Authors:  Marilyn J Telen
Journal:  Blood       Date:  2016-01-12       Impact factor: 22.113

4.  Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality.

Authors:  Gregory J Kato; Sabrina Martyr; William C Blackwelder; James S Nichols; Wynona A Coles; Lori A Hunter; Marie-Luise Brennan; Stanley L Hazen; Mark T Gladwin
Journal:  Br J Haematol       Date:  2005-09       Impact factor: 6.998

5.  P-selectin plays a role in haem-induced acute lung injury in sickle mice.

Authors:  Samit Ghosh; Bethany Flage; Frances Weidert; Solomon F Ofori-Acquah
Journal:  Br J Haematol       Date:  2019-02-27       Impact factor: 6.998

Review 6.  Redox-dependent impairment of vascular function in sickle cell disease.

Authors:  Mutay Aslan; Bruce A Freeman
Journal:  Free Radic Biol Med       Date:  2007-08-31       Impact factor: 7.376

Review 7.  Selectins: initiators of leucocyte adhesion and signalling at the vascular wall.

Authors:  Rodger P McEver
Journal:  Cardiovasc Res       Date:  2015-05-20       Impact factor: 10.787

Review 8.  Advances in sickle cell therapies in the hydroxyurea era.

Authors:  Joshua J Field; David G Nathan
Journal:  Mol Med       Date:  2014-12-16       Impact factor: 6.354

9.  Review of Medication Therapy for the Prevention of Sickle Cell Crisis.

Authors:  Tanya R Riley; Angelo Boss; Dominique McClain; Treavor T Riley
Journal:  P T       Date:  2018-07

Review 10.  State of the Art Management of Acute Vaso-occlusive Pain in Sickle Cell Disease.

Authors:  Latika Puri; Kerri A Nottage; Jane S Hankins; Doralina L Anghelescu
Journal:  Paediatr Drugs       Date:  2018-02       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.